全文获取类型
收费全文 | 12679篇 |
免费 | 842篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 100篇 |
儿科学 | 242篇 |
妇产科学 | 239篇 |
基础医学 | 1785篇 |
口腔科学 | 294篇 |
临床医学 | 1612篇 |
内科学 | 2399篇 |
皮肤病学 | 99篇 |
神经病学 | 1157篇 |
特种医学 | 394篇 |
外科学 | 1626篇 |
综合类 | 153篇 |
一般理论 | 13篇 |
预防医学 | 1426篇 |
眼科学 | 224篇 |
药学 | 1014篇 |
中国医学 | 13篇 |
肿瘤学 | 757篇 |
出版年
2023年 | 73篇 |
2022年 | 87篇 |
2021年 | 223篇 |
2020年 | 168篇 |
2019年 | 230篇 |
2018年 | 304篇 |
2017年 | 207篇 |
2016年 | 229篇 |
2015年 | 285篇 |
2014年 | 386篇 |
2013年 | 575篇 |
2012年 | 902篇 |
2011年 | 970篇 |
2010年 | 522篇 |
2009年 | 538篇 |
2008年 | 876篇 |
2007年 | 925篇 |
2006年 | 907篇 |
2005年 | 915篇 |
2004年 | 921篇 |
2003年 | 807篇 |
2002年 | 771篇 |
2001年 | 146篇 |
2000年 | 125篇 |
1999年 | 132篇 |
1998年 | 151篇 |
1997年 | 131篇 |
1996年 | 96篇 |
1995年 | 72篇 |
1994年 | 71篇 |
1993年 | 57篇 |
1992年 | 60篇 |
1991年 | 53篇 |
1990年 | 58篇 |
1989年 | 55篇 |
1988年 | 42篇 |
1987年 | 52篇 |
1986年 | 52篇 |
1985年 | 43篇 |
1984年 | 36篇 |
1983年 | 38篇 |
1982年 | 31篇 |
1981年 | 36篇 |
1980年 | 28篇 |
1979年 | 17篇 |
1978年 | 17篇 |
1977年 | 19篇 |
1976年 | 21篇 |
1975年 | 12篇 |
1971年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Deitelzweig Steve Luo Xuemei Nguyen Jennifer L. Malhotra Deepa Emir Birol Russ Cristina Li Xiaoyan Lee Theodore C. Ferri Mauricio Wiederkehr Danny Reimbaeva Maya Barnes Geoffrey D. Piazza Gregory 《Journal of thrombosis and thrombolysis》2022,54(4):696-696
Journal of Thrombosis and Thrombolysis - 相似文献
3.
R. E. J. Ryder 《Diabetic medicine》2015,32(3):305-313
On 8 April 2014, a US jury ordered Takeda and Eli Lilly to pay $9 bn in punitive damages after finding that they had concealed the cancer risks associated with pioglitazone. By contrast, on 28 August 2014, the long‐awaited outcome of the 10‐year Kaiser Permanente Northern California study was announced. That study was specifically designed to investigate whether patients exposed to pioglitazone were at an increased risk of bladder cancer and found no association; thus, at last, the controversial issue has been resolved. A review, in retrospect, of the story of the proposed link between pioglitazone and bladder cancer reveals flaws at every stage. In 2012, a BMJ editorial, in keeping with some other contemporary reports, stated ‘it can confidently be assumed that pioglitazone increases the risk of bladder cancer’. Examination of the information which led to such a statement shows that: 1) the pre‐clinical findings of bladder cancer in male rats is not indicative of human risk; 2) there is no association between bladder cancer and pioglitazone in randomized controlled trials, once cases that could not plausibly be related to treatment are removed; and 3) the observational studies that have suggested a link have over‐extrapolated from the data: pioglitazone‐treated patients had more risk factors for bladder cancer than those not treated with pioglitazone. Meanwhile careful study of randomized controlled trials shows evidence of cardiovascular benefit from pioglitazone in Type 2 diabetes, a condition which results, more than anything, in premature cardiovascular death and morbidity. 相似文献
4.
5.
James I. Geller MD Joseph G. Pressey MD Malcolm A. Smith MD Rachel A. Kudgus PhD Mariana Cajaiba MD Joel M. Reid PhD David Hall PhD Donald A. Barkauskas PhD Stephen D. Voss MD Steve Y. Cho MD Stacey L. Berg MD Jeffrey S. Dome MD PhD Elizabeth Fox MD Brenda J. Weigel MD 《Cancer》2020,126(24):5303-5310
6.
Pulmonary hamartomas are usually an incidental finding and range in size from 1 cm to 8 cm in diameter in various series. We report a case of a massive pulmonary hamartoma (size 25.5 × 17.5 × 6.5 cm and weighing 1134 g) in a 61 year old male who presented with a short history of breathlessness. The tumour was arising from the medial border of the right lung and occupying most of the right chest extending in to the anterior mediastinum. The tumour was compressing the right lung and there was no evidence of infiltration into the surrounding structures. It was successfully treated by surgical resection and final histology was pulmonary hamartoma with predominantly adipose and leiomyomatous differentiation. 相似文献
7.
Steve Vucic Kevin D Cairns Kristin R Black Peter Siao Tick Chong Didier Cros 《Clinical neurophysiology》2006,117(2):392-397
OBJECTIVE: Cervical nerve root stimulation (CRS) is a technique of assessing the proximal segments of motor axons destined to upper extremity muscles. Few studies report normal values. The objective was to determine CMAP onset-latencies and CMAP amplitude, area, and duration changes in healthy controls for the abductor pollicis brevis (APB), abductor digiti minimi (ADM), biceps, and riceps muscles. In addition, to determine the tolerability of CRS, as measured by the visual analog scale (VAS). METHODS: We studied 21 healthy volunteers prospectively with CRS using four target muscles (APB, ADM, biceps, and triceps) bilaterally. Collision studies were used in all APB recordings. VAS was obtained in all subjects. RESULTS: Mean CMAP onset-latencies were: APB 14 +/- 1.5 ms; ADM 14.2 +/- 1.5 ms; biceps 5.4 +/- 0.6 ms; triceps 5.4 +/- 1.0 ms. Onset-latency significantly correlated with height for all nerves. The mean change in CMAP amplitude and area (%) between most distal stimulation and CRS was: APB reduction of 15.1 +/- 11.6 and 4.9 +/- 3.6%; ADM reduction of 21.1 +/- 10.7 and 17.2 +/- 8.8; biceps reduction of 10 +/- 11.5 and reduction of 8.7 +/- 6.8; triceps increase of 3.3 +/- 5.2 and 11.0 +/- 9.9% respectively. Mean CMAP duration change between most distal stimulation and CRS was: APB, increase of 20.4 +/- 7.4%; ADM, increase of 14.4 +/- 8.5%; biceps, increase of 13.9 +/- 10.8%; triceps, increase of 7.7 +/- 6.7%. The mean VAS score was 3.8 +/- 1.2, and all subjects completed the study. CONCLUSIONS: The present study establishes normative data and indicates that CRS is a well-tolerated technique. SIGNIFICANCE: The normal values may be used as reference data for the needle CRS technique in the assessment of proximal conduction abnormalities. 相似文献
8.
David M Dohan Joseph Choukroun Antoine Diss Steve L Dohan Anthony J J Dohan Jaafar Mouhyi Bruno Gogly 《Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics》2006,101(3):e37-e44
Platelet-rich fibrin (PRF) belongs to a new generation of platelet concentrates geared to simplified preparation without biochemical blood handling. In this initial article, we describe the conceptual and technical evolution from fibrin glues to platelet concentrates. This retrospective analysis is necessary for the understanding of fibrin technologies and the evaluation of the biochemical properties of 3 generations of surgical additives, respectively fibrin adhesives, concentrated platelet-rich plasma (cPRP) and PRF. Indeed, the 3-dimensional fibrin architecture is deeply dependent on artificial clinical polymerization processes, such as massive bovine thrombin addition. Currently, the slow polymerization during PRF preparation seems to generate a fibrin network very similar to the natural one. Such a network leads to a more efficient cell migration and proliferation and thus cicatrization. 相似文献
9.
10.